STRATUS-US研究
Smoking Cessation in Smokers Motivated to Quit
Presented at
American College of Cardiology
Scientific Sessions 2004
Presented by Dr. Robert Anthenelli
STRATUS-US Trial
Rimonabant
A selective cannabinoid type 1 receptor antagonist
5 mg
n=262
Endpoints (1 year):
Smoking abstinence
Change in body weight in patients who stopped smoking
STRATUS-US Trial
Presented at ACC Scientific Sessions 2004
787 patients who smoked ≥10 cigarettes/day for at least 2 months and were motivated to stop smoking
Randomized, double-blind, multicenter
Placebo
n=261
Rimonabant
A selective cannabinoid type 1 receptor antagonist
20 mg
n=261
Treatment for 1 Year
STRATUS-US Trial
Smoking abstinence at 7-10 weeks
p < 0.001 for high-dose vs placebo
p = NS for low-dose vs placebo
Presented at ACC Scientific Sessions 2004
Smoking abstinence at end of study
p < 0.001 for high-dose vs placebo
p = NS for low-dose vs placebo
STRATUS-US Trial
Change in weight from baseline among patients with a prolonged abstinence from smoking
p<0.001 for rimonabant 20 mg vs placebo
Among patients with a prolonged abstinence from smoking, change in weight from baseline was significantly ? in high-dose group compared with placebo (Figure)
In subgroup of patients who were overweight initially, BMI was significantly ? in high-dose group versus placebo (-0.1 vs. 1.7, p<0.001)
Presented at ACC Scientific Sessions 2004
kg
STRATUS-US Trial
Among patients smoking ≥10 cigarettes per day and motivated to stop smoking, use of the selective cannabinoid type 1 receptor antagonist rimonabant in a 20 mg dose was associated with an increase in prolonged smoking abstinence compared with placebo, but there was no difference between the 5 mg dose of rimonabant and placebo
Additionally, weight gain, which can be a negative side effect of smoking cessation, was lower in patients who received rimonabant 20 mg, with benefit seen even in obese patients
Further evaluation warranted